ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different tumor types includin
Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
Ipsen (@IpsenGroup) / Twitter
Philippe Lopes-Fernandes on LinkedIn: Ipsen to acquire Epizyme, expanding oncology portfolio
Press Releases - Ipsen
Ipsen nomme Gwenan White en qualité de Vice-Président Exécutif, Communication et Affaires Publiques | Business Wire
PRESS RELEASE Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patie
PRESS RELEASE
PRESS RELEASE
Ipsen and Marengo Therapeutics announce strategic partnership to advance two precision immuno-oncology candidates from Marengo S
Press Releases - Ipsen UK
Press Releases - Ipsen UK
Press Releases - Ipsen UK
News articles listing - Ipsen
PRESS RELEASE
PRESS RELEASE Oncodesign et Ipsen signent un partenariat stratégique en oncologie et Oncodesign intègre le Campus d'Ipsen à
AGV Discovery Press Release French - FINAL
PRESS RELEASE Ipsen announces new data to be presented at ASCO in line with its continued commitment to Oncology research
Press Releases - Ipsen
Ipsen NHS Study Published - IFOPA - International Fibrodysplasia Ossificans Progressiva Association
PRESS RELEASE Ipsen announces acceptance of filings for Somatuline in the treatment of GEP-NETs in the US with priority review a
Ipsen acquiert Epizyme et étend son portefeuille en Oncologie | Business Wire
Ipsen intègre un nouveau programme à son portefeuille R&D de produits d'oncologie en phase pré-clinique grâce à une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la protéine modificatrice d'ARN METTL3 | Business
PRESS RELEASE
Press Releases - Ipsen UK
